Published On: Thu, Aug 28th, 2014

Teva Recalling Parkinson’s Drug Batch in US

carbidopa-levodopa

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled a batch of its generic Parkinson’s combination drug treatment carbidopa/levodopa because of concern that it may contain too much active pharmaceutical ingredient.

The company said that the Class II recall involved 3, 881 bottles of 25 or 100mg carbidopa/levodopa. Teva added that stability testing found that the product might be “superpotent.” The voluntary recall is for the entire US.

A class II recall as defined by the US Food and Drug Administration (FDA) means that use of a drug could cause temporary damage to health.

Published by Globes [online], Israel business news – www.globes-online.com – on August 28, 2014

Read more about: , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems